Licraside as novel potent FXR agonist for relieving cholestasis: structure-based drug discovery and biological evaluation studies

Licraside as novel potent FXR agonist for relieving cholestasis: structure-based drug discovery and biological evaluation studies

Cholestasis is a common clinical disease caused by a disorder in bile acids (BAs) homeostasis, which promotes its development. The Farnesoid X receptor (FXR) plays a critical role in regulating BAs homeostasis, making it an essential target for cholestasis treatment. Although several active FXR agon...

Full description

Bibliographic Details
Main Authors: Lili Xi, Axi Shi, Tiantian Shen, Guoxu Wang, Yuhui Wei, Jingjing Guo
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-06-01
Series:Frontiers in Pharmacology
Subjects:
FXR
licraside
agonist
cholestasis
virtual screening
biological evaluation
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1197856/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1197856/full

Similar Items